Lexicon Pharmaceuticals continues to receive incentives from the Food & Drug Administration to keep developing the drug telotristat for the treatment of carcinoid syndrome, a condition caused by tumors in the GI tract.
The FDA has awarded orphan drug status to telotristat. The company's drug was previously awarded fast-track status as well, allowing Lexicon to submit its marketing application in stages and not all at once, giving them more interaction with FDA regulators and even, potentially, a priority review.
Telotristat is an oral drug that reduces serotonin levels. Tumors from carcinoid syndrome cause an increased production of serotonin, amounting to a variety of side effects including severe diarrhea.
Source: Therapeutics Daily
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
